

Supplementary Figure 1 Prevalence of lumbar puncture procedure among patients with advanced human immunodeficiency virus disease who screened for serum cryptococcal antigen in Africa: Sensitivity analysis.

Omitted study				Effect size with 95% CI	p-value
Boyd et al, (2022)			•	- 0.7 [0.6, 0.8]	0.000
Blasich et al, (2021)			•	0.7 [0.6, 0.8]	0.000
Longley et al, (2016)			•	- 0.7 [0.6, 0.8]	0.000
Enock et al, (2022)			-	0.7 [0.6, 0.8]	0.000
Tiam et al, (2023)			•	0.7 [0.5, 0.8]	0.000
Blankley et al, (2019)			-	0.7 [0.6, 0.8]	0.000
Heller et al, (2022)			_	- 0.7 [0.6, 0.8]	0.000
Kanyama et al, (2022)			•	0.7 [0.5, 0.8]	0.000
Hurt et al, (2021)			•	- 0.7 [0.6, 0.8]	0.000
Deiss et al, (2021)			•	0.7 [0.6, 0.8]	0.000
Braide et al, (2023)			•	- 0.7 [0.6, 0.8]	0.000
Bornstein et al, (2014)			•	0.7 [0.6, 0.8]	0.000
Faini et al, (2019)			•	0.7 [0.6, 0.8]	0.000
Ndayishimiye et al, (2018)			•	— 0.7 [0.6, 0.8]	0.000
Temfack et al, (2018)			•	0.7 [0.6, 0.8]	0.000
Mamuye et al, (2016)			•	0.7 [0.5, 0.8]	0.000
Pac et al, (2015)			•	0.7 [0.6, 0.8]	0.000
Nalintya et al, (2018)			•	— 0.7 [0.6, 0.8]	0.000
Oyella et al , (2012)			•	- 0.7 [0.6, 0.8]	0.000
Ssebambulidde et al, (2019)			•	0.7 [0.5, 0.8]	0.000
Zono et al, (2024)			•	0.7 [0.6, 0.8]	0.000
Eigege et al, (2024)		-	•	-0.7 [0.6, 0.8]	0.000
Smitson et al, (2014)			•	-0.7 [0.6, 0.8]	0.000
Eric et al, (2023)			•	0.7 [0.6, 0.8]	0.000
Tufa et al, (2017)			•	0.7 [0.5, 0.8]	0.000
Wajanga et al, (2011)			•	0.7 [0.5, 0.8]	0.000
Magambo et al, (2014)			•	0.7 [0.5, 0.8]	0.000
Wake et al, (2018)			•	- 0.7 [0.6, 0.8]	0.000
Makadzange et al, (2021)			•	- 0.7 [0.6, 0.8]	0.000
Blanco-Arévalo et al, (2019)			•	0.7 [0.5, 0.8]	0.000
Lakoh et al, (2020)			•	0.7 [0.5, 0.8]	0.000
	.5	.6	.7	.8	

Supplementary Figure 2 Influential analysis on the overall prevalence of lumbar puncture procedure uptake among patients with advanced human immunodeficiency virus disease who screened for serum cryptococcal antigen in Africa.

Omitted study		Effect size with 95% CI	p-value
Boyd et al, (2022)	•	0.6 [0.4, 0.7]	0.000
Blasich et al, (2021)	•	0.6 [0.4, 0.7]	0.000
Longley et al, (2016)		0.5 [0.4, 0.7]	0.000
Tiam et al, (2023)		0.5 [0.4, 0.7]	0.000
Blankley et al, (2019)		0.5 [0.4, 0.7]	0.000
Heller et al, (2022)		0.5 [0.4, 0.7]	0.000
Kanyama et al, (2022)		0.5 [0.4, 0.7]	0.000
Deiss et al, (2021)		0.5 [0.4, 0.7]	0.000
Braide et al, (2023)	•	0.6 [0.4, 0.7]	0.000
Bornstein et al, (2014)		0.5 [0.4, 0.7]	0.000
Faini et al, (2019)	•	0.6 [0.4, 0.7]	0.000
Mamuye et al, (2016)		0.5 [0.4, 0.7]	0.000
Pac et al, (2015)		0.6 [0.4, 0.7]	0.000
Nalintya et al, (2018)		0.5 [0.4, 0.7]	0.000
Oyella et al , (2012)		0.5 [0.4, 0.7]	0.000
Ssebambulidde et al, (2019)	• • • • • • • • • • • • • • • • • • •	0.5 [0.4, 0.6]	0.000
Zono et al, (2024)		0.5 [0.4, 0.7]	0.000
Eigege et al, (2024)	·	0.5 [0.4, 0.7]	0.000
Eric et al, (2023)		0.5 [0.4, 0.6]	0.000
Wajanga et al, (2011)	•	0.5 [0.4, 0.6]	0.000
Magambo et al, (2014)		0.6 [0.5, 0.7]	0.000
Wake et al, (2018)		0.5 [0.4, 0.7]	0.000
Makadzange et al, (2021)	•	0.6 [0.4, 0.7]	0.000
Blanco-Arévalo et al, (2019)		0.5 [0.4, 0.7]	0.000
Lakoh et al, (2020)		0.5 [0.4, 0.7]	0.000
	.4 .5 .6	7.7	

Supplementary Figure 3 Influential analysis on the overall prevalence of cryptococcal meningitis among patients with advanced human immunodeficiency virus disease who screened positive for serum cryptococcal antigen in Africa.

Omitted study					Effect size with 95% CI	p-value
Longley et al, (2016)		•			0.1 [0.0, 0.1]	0.001
Kanyama et al, (2022)			•		- 0.1 [0.0, 0.1]	0.000
Hurt et al, (2021)					0.1 [0.0, 0.1]	0.001
Deiss et al, (2021)			•		- 0.1 [0.0, 0.1]	0.000
Faini et al, (2019)					0.1 [0.0, 0.1]	0.001
Mamuye et al, (2016)			<u> </u>		0.1 [0.0, 0.1]	0.000
Pac et al, (2015)			•		-0.1 [0.0, 0.1]	0.000
Nalintya et al, (2018)			•		-0.1 [0.0, 0.1]	0.000
Smitson et al, (2014)			•		- 0.1 [0.0, 0.1]	0.000
Tufa et al, (2017)			•		- 0.1 [0.0, 0.1]	0.000
Wajanga et al, (2011)					0.1 [0.0, 0.1]	0.001
Wake et al, (2018)			•		-0.1 [0.0, 0.1]	0.000
Wake et al, (2020)		•			0.1 [0.0, 0.1]	0.001
Makadzange et al, (2021)		•			0.1 [0.0, 0.1]	0.001
Blanco-Arévalo et al, (2019)			•		- 0.1 [0.0, 0.1]	0.000
Lakoh et al, (2020)			•		- 0.1 [0.0, 0.1]	0.000
	0	.05		.1	-	

Supplementary Figure 4 Influential analysis on the overall prevalence of mortality among patients with advanced human immunodeficiency virus disease who screened for serum cryptococcal antigen in Africa.